investig
whether
circul
osteopontin
opn
could
use
biomark
cervic
cancer
employ
monoclon
antibodi
mab
specif
uniqu
intact
thrombinsensit
site
opn
use
inhibit
elisa
found
significantli
higher
level
opn
cervic
cancer
patient
plasma
mean
sd
ng
ml
serum
ngml
compar
healthi
subject
ngml
plasma
sampl
p
ngml
serum
sampl
p
respect
similar
result
obtain
plasma
bigger
group
individu
cervic
cancer
patient
ngml
compar
plasma
sampl
healthi
individu
p
significantli
opn
level
highest
stage
iiiiv
diseas
ngml
individu
p
least
nondiscriminatori
stage
ngml
individu
p
discrimin
found
mab
differ
specif
mab
use
similar
inhibit
elisa
compar
two
group
first
studi
commerci
captur
elisa
also
fail
possibl
target
epitop
recogn
antibodi
probe
assay
absent
circul
opn
due
protein
truncat
support
gel
fraction
opn
found
patient
plasma
kda
fragment
found
instead
presum
fulllength
opn
kda
seen
healthi
peopl
fragment
gener
possibl
role
play
cancer
biolog
remain
interest
question
member
famili
small
integrinbind
ligand
nlink
glycophosphoprotein
sibl
opn
highli
conserv
among
mammal
human
opn
amino
acid
includ
uniqu
conserv
thrombinsensit
site
cleavag
site
thrombin
normal
occur
circul
fragment
protein
roughli
two
equal
halv
differ
biolog
activ
aminotermin
half
protein
bind
varieti
cell
surfac
integrin
arginineglycineaspart
rgd
motif
protein
also
integrin
thrombingener
site
svvyglr
carboxytermin
half
interact
cell
surfac
splice
variant
variou
extracellular
interact
thrombinactiv
opn
play
pivot
role
divers
physiolog
process
bone
remodel
inflamm
wound
heal
well
variou
patholog
includ
autoimmun
tumor
metastasi
progress
thrombinactiv
opn
also
report
inhibit
apoptosi
promot
surviv
prolifer
cancer
cell
recent
opn
shown
exert
intracellular
function
affect
divers
cellular
process
tumor
progress
product
dendrit
cell
function
requir
opn
protein
appropri
cleav
thrombin
variou
caspas
produc
appropri
truncat
rna
splice
variant
extracellularli
variou
metalloproteinas
mmp
also
cleav
opn
variou
type
fragment
variou
tumorigen
biolog
activ
overexpress
opn
form
mrna
transcript
intracellular
protein
observ
tumor
tissu
deriv
breast
lung
cancer
ovarian
cancer
cervic
cancer
significantli
increas
level
circul
opn
also
report
sever
type
cancer
includ
cervic
cancer
prostat
cancer
colorect
cancer
howev
conflict
report
regard
head
neck
squamou
cell
carcinoma
addit
differ
diagnost
kit
found
yield
quit
differ
result
one
anoth
patient
sampl
interest
use
noninvas
method
examin
cervic
cancer
patient
type
cancer
common
hong
kong
highli
invas
lethal
sinc
diseas
progress
rapidli
asymptomat
preclinicalles
overt
cancer
disappoint
result
obtain
initi
use
commerci
opn
detect
kit
consequ
decid
devis
detect
assay
herein
describ
develop
assay
base
use
uniqu
monoclon
antibodi
assay
format
use
infrequentlyinhibit
elisa
osteopontin
opn
known
previous
secret
phosphoprotein
earli
tlymphocyt
activ
protein
initi
identifi
extracellular
matrix
protein
produc
osteoclast
consid
pleiotrop
proinflammatori
purchas
r
system
minneapoli
mn
cat
sigma
st
loui
md
cat
thrombin
glutathionecoupl
sepharos
bead
obtain
amersham
bioscienc
piscataway
nj
protein
gcoupl
sepharos
bead
proteas
inhibitor
cocktail
pmsf
tmb
pma
fitcconjug
goat
antimous
ig
antibodi
nhydroxysucinimidobiotin
obtain
sigma
biogel
variou
retent
limit
kda
kda
kda
kda
obtain
biorad
laboratori
berkeley
ca
human
opn
assay
kit
obtain
immunobiolog
laboratori
ibl
co
ltd
gunma
japan
preoper
pair
plasma
serum
sampl
obtain
consent
first
cohort
patient
diagnos
cervic
cancer
patient
squamou
cell
carcinoma
patient
adenocarcinoma
age
rang
year
mean
sd
year
second
cohort
cervic
cancer
patient
patient
diseas
stage
age
rang
year
mean
sd
year
patient
diseas
stage
ii
age
rang
year
mean
sd
year
patient
diseas
stage
iiiiv
age
rang
year
mean
sd
year
depart
obstetr
gynecolog
princ
wale
hospit
hong
kong
control
plasma
sampl
healthi
women
age
rang
year
mean
sd
year
serum
sampl
age
rang
year
mean
sd
year
sent
routin
laboratori
test
use
sampl
store
use
data
analyz
anonym
studi
approv
joint
chines
univers
hong
kongnew
territori
east
cluster
clinic
research
ethic
committe
bacteri
deriv
recombin
human
opn
ntermin
ctermin
half
gener
gst
fusion
protein
opnogst
opnpgst
respect
escherichia
coli
use
express
vector
amersham
bioscienc
previous
describ
cdna
obtain
cell
pcramplifi
gener
dna
fragment
use
follow
forward
f
primer
revers
r
primer
opno
aa
f
contain
site
underlin
r
contain
site
underlin
opnp
aa
f
contain
site
underlin
r
contain
smai
site
underlin
subclon
vector
fusion
protein
deriv
construct
induc
purifi
affin
chromatographi
examin
sdspage
commassi
blue
stain
wb
insectcel
deriv
recombin
human
opn
gener
peptidetag
fusion
protein
use
baculodirect
baculoviru
express
system
accord
manufactur
instruct
invitrogen
cdna
obtain
cell
pcramplifi
gener
dna
fragment
use
follow
forward
f
primer
contain
kozak
sequenc
underlin
revers
r
primer
opno
f
r
opnp
f
r
subclon
entri
vector
invitrogen
purifi
plasmid
insert
right
orient
recombin
baculodirect
linear
dna
incub
lr
clonas
overnight
room
temperatur
cell
grow
logphas
transfect
recombin
dna
mixtur
cellfectin
invitrogen
select
mm
ganciclovir
low
titer
viru
prepar
viral
stock
bear
opno
opnp
gene
construct
harvest
spent
cultur
supernat
day
posttransfect
ganciclovir
select
less
cell
infect
reveal
antibodi
stain
ifa
high
titer
viru
prepar
viral
stock
harvest
cell
inocul
aliquot
viral
stock
day
ganciclovir
select
cell
infect
fusion
protein
obtain
lysat
cell
incub
viral
stock
without
select
hr
almost
cell
infect
time
harvest
reveal
antibodi
stain
cytosol
extract
prepar
incub
infect
cell
lysi
buffer
mm
nacl
mm
tri
ph
proteas
inhibitor
mm
pmsf
min
follow
centrifug
rpm
min
cultur
supernat
x
ml
cell
without
treatment
pma
ngml
hr
harvest
concentr
origin
volum
centrifug
rpm
min
centricon
kda
cutoff
millipor
billerica
sampl
store
analysi
balbc
mice
hyperimmun
purifi
bacteriallyderiv
opnogst
opnpgst
protein
spleen
cell
obtain
anim
fuse
myeloma
cell
describ
hybridoma
obtain
screen
reactiv
insect
cellderiv
recombin
protein
directbind
elisa
posit
hybridoma
character
ifa
wb
monoclon
antibodi
select
clone
mab
mab
mab
obtain
spentcultur
supernat
ascit
fluid
purifi
ammonia
sulfat
precipit
case
antibodi
prote
select
biotinyl
use
nhydroxysucinimidobiotin
opn
detect
determin
abil
test
sampl
human
serum
plasma
cultur
supernat
block
bind
opnspecif
indic
antibodi
mab
mab
mab
insolubil
antigen
bacteriallyderiv
opnogst
mab
opnpgst
mab
fulllength
opn
concentr
indic
antibodi
use
determin
previous
titrat
antibodi
respect
antigen
base
od
max
thu
well
elisa
plate
immunlon
ii
dynatech
chantilli
va
coat
differ
antigen
use
bicarbon
buffer
ph
fifti
dilut
sampl
plasma
serum
dilut
ratio
mix
dilut
indic
antibodi
incub
immobil
antigen
hr
wash
bound
indic
antibodi
detect
use
hrpconjug
goat
antimous
ig
hr
tmb
result
read
od
nm
elisa
reader
calibr
curv
construct
experi
use
serial
dilut
fulllength
opn
ngml
employ
determin
whether
mab
mab
share
common
bind
site
opn
thu
serial
dilut
mab
competitor
mix
biotincoupl
mab
predetermin
concentr
incub
immobil
opnogst
overnight
cold
unbiotinyl
mab
use
posit
control
follow
wash
bound
indic
antibodi
detect
incub
hrpconjug
streptavidin
hr
reaction
develop
use
tmb
result
read
od
nm
bind
specif
confirm
revers
assay
use
mab
competitor
biotincoupl
mab
indic
cytospin
prepar
cell
express
opnoor
protein
methanolfix
block
bsa
stain
reagent
mab
min
room
temperatur
follow
incub
fitcconjug
goat
antimous
ig
antibodi
min
room
temperatur
cell
examin
uv
microscopi
antibodi
invitrogen
use
posit
control
recombin
protein
cell
lysat
treat
reduc
sampl
buffer
min
resolv
sdspage
gel
transfer
pvdf
membran
membran
block
bsa
later
incub
detect
mab
mab
mab
overnight
follow
membran
incub
hrpconjug
goat
antimous
ig
antibodi
hr
room
temperatur
membran
thoroughli
wash
use
film
develop
ecl
chemoluminesc
amersham
bioscienc
fulllength
opn
ng
incub
grade
dose
thrombin
uml
trisbuff
ph
hr
heat
reduc
sampl
buffer
min
sampl
resolv
sdspage
gel
transfer
pvdf
membran
examin
wb
mabprotect
studi
opn
ng
preincub
grade
dose
mab
trisbuff
ph
overnight
follow
incub
uml
thrombin
hr
sampl
treat
reduc
sampl
buffer
min
resolv
sdspage
gel
transfer
pvdf
membran
examin
wb
minicolumn
ml
bedsiz
prepar
use
biogel
biorad
laboratori
berkeley
ca
differ
retent
limit
kda
kda
kda
kda
thoroughli
equilibr
pb
repeat
load
subsequ
centrifug
x
g
min
column
first
calibr
use
blue
dextran
dnplysin
experi
human
plasma
load
column
centrifug
x
g
min
eluat
collect
column
load
pb
centrifug
eluat
collect
procedur
pbsload
repeat
sampl
eluat
fraction
obtain
opn
concentr
fraction
determin
use
mab
inhibit
elisa
control
bovin
serum
albumin
mgml
also
run
column
use
procedur
protein
content
fraction
determin
use
bicinchonin
acid
bca
protein
assay
kit
pierc
rockford
microdissect
tumor
tissu
rna
extract
process
tissu
well
revers
transcript
realtim
pcr
extract
rna
perform
describ
comparison
differ
two
group
perform
use
unpair
ttest
correl
group
data
perform
use
regress
analysi
pvalu
consid
statist
signific
variabl
data
express
scatterplot
analysi
graphpad
prism
graphpad
softwar
inc
san
diego
ca
recombin
opn
protein
produc
e
coli
dna
clone
cell
thu
two
gstlink
opn
fragment
obtain
one
repres
roughli
ntermin
half
opno
ctermin
half
opnp
protein
fig
correspond
protein
fragment
also
express
insect
cell
fig
ten
hybridoma
produc
mice
immun
opno
opnp
clone
bound
well
bacteri
opno
mab
mab
igg
antibodi
recogn
linear
epitop
elisa
ifa
wb
mab
also
igg
recogn
conform
epitop
elisa
ifa
wb
opnpspecif
antibodi
mab
mab
mab
mab
igm
bound
linear
epitop
mab
mab
mab
bound
specif
elisa
recombin
opn
antigen
deriv
bacteria
insect
cell
fig
bind
compar
fulllength
opn
obtain
commerci
fig
mab
mab
bound
differ
site
opno
sinc
crossinhibit
fig
three
mab
specif
bind
also
demonstr
wb
analysi
fig
immunofluorescencestain
insect
cell
transfect
respect
opn
gene
fig
discov
chanc
mab
recogn
evolutionaryconserv
uniqu
thrombinsensit
site
arg
ser
opn
see
fig
first
known
digest
opn
thrombin
produc
two
fragment
roughli
equal
size
accordingli
incub
intact
opn
obtain
commerci
increas
amount
thrombin
monitor
result
use
mab
elisa
detect
much
intact
opn
remain
increas
degrad
observ
increas
enzym
fig
contrast
effect
observ
probe
mab
fig
secondli
use
mab
probe
fulllength
opn
could
observ
kda
band
western
blot
disappear
complet
protein
pretreat
uml
thrombin
fig
upper
panel
smaller
amount
thrombin
littl
effect
mab
use
probe
blot
u
ml
thrombin
use
also
signific
reduct
amount
fulllength
opn
reason
unclear
disappear
complet
importantli
addit
antigen
kda
appear
fig
lower
panel
thirdli
mab
abl
protect
opn
thrombin
digest
dosedepend
fashion
fig
concentr
detect
antibodi
use
predetermin
titrat
curv
mab
data
shown
chosen
maxim
bind
fig
fulllength
opn
obtain
commerci
produc
mous
cell
histidin
tag
protein
use
standard
assay
sensit
determin
concentr
fulllength
opn
ngml
requir
inhibit
maxim
antibodi
bind
sensit
obtain
differ
assay
shown
fig
particular
note
excel
detect
mab
ngml
opnogst
use
substrat
compar
poor
detect
mab
ngml
antibodi
detect
commerciallyobtain
fulllength
opn
poorli
ngml
detect
mab
extrem
poor
opn
substrat
inhibit
elisa
develop
use
either
mab
mab
reagent
antibodi
bacteriallyproduc
opnogst
substrat
assay
effici
specif
detect
appropri
opn
produc
insect
cell
mous
cell
fig
interestingli
howev
mab
fold
sensit
mab
detect
opn
produc
cell
fig
next
use
mab
opnogst
inhibit
elisa
detect
opn
plasma
cervic
cancer
patient
squamou
cell
carcinoma
adenocarcinoma
cervic
intraepitheli
neoplasia
cin
grade
iii
found
highli
signific
p
level
opn
mean
sd
ngml
patient
compar
healthi
subject
ngml
fig
base
sampl
size
discrimin
highli
signific
minimum
patient
control
requir
confid
power
respect
assay
sensit
specif
similar
result
found
serum
individu
examin
cancer
patient
ng
ml
significantli
p
higher
level
opn
healthi
subject
ng
ml
fig
assay
sensit
specif
respect
fact
good
correl
r
p
plasma
serum
opn
level
cervic
cancer
patient
fig
even
though
serum
level
significantli
lower
correspond
plasma
level
howev
base
sampl
size
discrimin
patient
control
robust
minimum
patient
control
requir
confid
power
respect
comparison
mab
use
inhibit
base
plasma
discrimin
cancer
healthi
group
fig
also
case
use
correl
small
number
patient
found
posit
kit
mab
inhibit
elisa
correspond
patient
mab
inhibit
elisa
fig
extend
mab
inhibit
elisa
studi
use
cervic
cancer
patient
plasma
time
identifi
stage
diseas
well
order
make
precis
correl
opn
level
diseas
thu
excel
discrimin
p
new
cohort
patient
ngml
healthi
subject
mean
ngml
fig
interestingli
patient
subdivid
accord
stage
diseas
fig
discrimin
seen
stage
ii
ngml
p
pronouncedli
stage
iiiiv
ngml
p
stage
ngml
p
tumor
tissu
avail
patient
stage
stage
ii
stage
cohort
use
determin
opn
gene
express
shown
fig
good
concord
r
p
plasma
opn
result
opn
gene
express
result
thu
valid
immunolog
detect
find
mab
inhibit
elisa
commerci
opn
kit
could
detect
elev
opn
level
cancer
patient
suggest
possibl
opn
present
could
fragment
ie
target
site
antibodi
use
assay
could
miss
wherea
virtu
design
mab
assay
thrombinsensit
site
must
present
thu
fraction
plasma
cancer
patient
gel
chromatographi
use
small
long
thin
column
made
biogel
differ
pore
size
serial
ml
fraction
collect
assay
opn
activ
use
mab
inhibit
elisa
column
precalibr
blue
dextran
dnplysin
bsa
protein
similar
molecular
size
kda
intact
opn
around
kda
shown
fig
bsa
total
exclud
exclus
limit
kda
kda
case
bulk
protein
appear
fraction
rest
fraction
kda
kda
elut
howev
bsa
exclud
instead
appear
mainli
fraction
smaller
amount
fraction
none
thereaft
plasma
pool
four
cervic
cancer
patient
select
basi
high
opn
activ
similarli
fraction
opn
total
exclud
bulk
activ
appear
fraction
fig
significantli
main
opn
activ
shift
fraction
elut
howev
littl
activ
recov
fraction
fraction
instead
spread
activ
fraction
fraction
peak
fraction
fraction
collect
find
suggest
cancer
patient
opn
exist
intact
protein
rather
fragment
kda
kda
size
interestingli
plasma
pool
healthi
individu
fraction
overal
fraction
profil
obtain
fig
slightli
differ
cancer
patient
thu
total
exclus
opn
activ
observ
spread
activ
includ
fraction
limit
confin
fraction
collect
suggest
protein
size
similar
bsa
kda
perform
western
blot
fraction
obtain
patient
control
subject
fig
use
mab
probe
result
consist
elisa
detect
significantli
patient
activ
detect
fraction
fraction
reveal
antigen
kda
size
present
small
amount
fraction
contain
marginallysmal
antigen
kda
significantli
greater
abund
antigen
found
modest
amount
fraction
turn
margin
smaller
size
kda
fraction
activ
contrast
western
blot
healthi
subject
antigen
activ
appear
earlier
fraction
close
void
volum
column
form
bulk
activ
sampl
molecular
size
antigen
roughli
kda
bigger
fragment
found
patient
smaller
antigen
kda
found
smaller
quantiti
subsequ
fraction
fraction
activ
observ
thereaft
sought
answer
import
question
cancer
diagnosi
opn
present
diagnost
level
blood
cervic
cancer
patient
found
convinc
evid
prove
howev
true
use
uniqu
mab
highlysensit
notsocommon
detect
system
mous
antibodi
mab
highli
specif
uniqu
thrombinsensit
site
opn
opn
effici
detect
patient
abil
block
bind
antibodi
target
antigen
thu
although
healthi
peopl
found
nomin
amount
opn
blood
assay
cancer
patient
show
significantli
higher
level
depend
sever
factor
discrimin
found
two
separ
cohort
cervic
cancer
patient
plasma
sampl
gave
better
result
serum
assay
reason
fact
blood
clot
form
serum
thrombin
activ
digest
opn
sampl
presum
condit
met
complet
degrad
protein
valid
plasma
mab
inhibit
elisa
result
shown
good
correl
result
correspond
serum
sampl
also
opn
gene
express
result
valid
seen
patient
regroup
accord
stage
diseas
opn
level
found
elisa
increas
sever
diseas
thu
sever
stage
iiiiv
show
highest
level
antigen
extrem
least
sever
stage
could
distinguish
healthi
individu
inde
abil
detect
stage
patient
possibl
pose
greatest
challeng
immunolog
assay
import
revel
studi
set
apart
past
public
find
opn
circul
patient
intact
protein
rather
fragment
kda
size
opn
fragment
infer
must
bear
intact
thrombinsensit
site
probabl
truncat
somewher
ntermin
end
protein
base
observ
two
immunoassay
use
parallel
mab
inhibit
elisa
fail
detect
similar
opn
increas
cancer
patient
inhibit
elisa
use
mab
detect
reagent
known
bind
ntermin
half
opn
actual
locat
unknown
commerciallyavail
captur
elisa
human
opn
detect
kit
ibl
employ
polyclon
antibodi
direct
two
site
opn
separ
aminoacid
one
ipvkqadsgsseekq
situat
ntermin
end
protein
fig
sinc
captur
assay
detect
fulllength
opn
effici
mab
inhibit
elisa
like
reason
failur
absenc
ntermin
site
patient
opn
fact
commerci
kit
success
use
type
cancer
previous
suggest
opn
might
cleav
differ
differ
enzym
differ
type
cancer
differ
individu
mani
opn
detect
kit
market
invari
use
captur
sandwich
elisa
differ
howev
pair
antibodi
util
term
fine
specif
also
whether
polyclon
monoclon
natur
polyclon
antibodi
target
small
peptideseg
protein
differ
antibodi
pair
use
affect
type
opn
fragment
detect
henc
vast
discord
among
test
kit
set
plasma
sampl
inhibit
elisa
develop
first
kind
opn
detect
distinct
advantag
format
fact
target
site
need
present
fragment
peptid
small
site
instruct
start
studi
actual
experi
pair
mab
eg
biotinylatedmab
mab
captur
elisa
detect
plasma
opn
patient
none
succeed
gener
inhibit
assay
common
one
proven
efficaci
detect
typhoid
fever
base
rapid
dualparticl
system
tubex
detect
singl
specif
antibodi
opn
fragment
indirectli
identifi
pool
patient
plasma
gel
filtrat
although
result
preliminari
need
verifi
robustli
term
sampl
size
methodolog
nevertheless
merit
discuss
compens
imprecis
fraction
biogel
column
care
calibr
use
known
marker
result
base
comparison
plasma
sampl
cancer
healthi
group
run
ident
condit
background
notabl
differ
elut
profil
two
group
inde
found
wherea
healthi
peopl
bulk
opn
antigen
activ
appear
void
fraction
fraction
cancer
group
appear
later
fraction
suggest
antigen
smaller
size
ie
cleav
support
seen
elut
profil
group
compar
thu
case
wherea
healthi
peopl
main
antigen
activ
found
fraction
appear
much
later
fraction
cancer
group
greater
spread
activ
western
blot
analysi
perform
fraction
use
antibodi
probe
mab
confirm
elisa
find
thu
main
antigen
activ
found
fraction
healthi
cancer
group
respect
instruct
antigen
found
patient
significantli
smaller
kda
observ
healthi
peopl
kda
seem
like
latter
intact
fulllength
opn
even
though
slightli
smaller
intact
opn
kda
produc
cell
use
earli
studythi
differ
could
due
posttransl
modif
see
later
thu
kda
antigen
found
patient
intact
major
fragment
interestingli
fragment
also
observ
healthi
peopl
minor
compon
patient
fragment
kda
fraction
kda
fraction
also
found
smaller
quantiti
possibl
three
antigen
actual
fragment
vari
degre
posttransl
modif
modif
increas
molecular
weight
protein
consider
highli
possibl
opn
although
protein
roughli
half
long
aminoacid
bsa
nevertheless
similar
molecular
weight
inde
opn
known
extens
phosphoryl
highli
activ
biolog
inde
mani
potenti
site
protein
phosphoryl
site
glycosyl
oglycosyl
nglycosyl
addit
protein
also
undergo
sulfat
transglutamin
possibl
candid
antigen
found
patient
major
fragment
cleav
whole
opn
enzym
cleav
opn
two
site
asp
fig
yield
two
major
peptid
aminoacid
long
respect
could
yield
molecular
weight
greater
kda
depend
extent
posttransl
modif
glycan
phosphat
appendag
matter
importantli
linear
antigen
western
blot
way
increas
molecular
weight
seem
affect
molecular
size
freeform
antigen
solut
thu
gel
chromatographi
opn
antigen
appear
like
globular
protein
molecular
weight
less
kda
ie
peptid
fewer
aminoacid
kda
antigen
deduc
western
blot
possibl
antigen
could
retard
passag
gel
due
interact
append
phosphat
carbohydr
group
biogel
resin
belittl
observ
opn
antigen
healthi
peopl
seem
unaffect
surpris
find
absenc
intact
opn
patient
argument
could
present
bound
thrombinsensit
site
cofactor
factor
h
becom
mask
rule
unlik
western
blot
result
factor
bound
opn
would
dissoci
denatur
condit
use
question
aris
whether
opn
fragment
found
patient
play
role
cancer
biolog
patient
one
hand
seem
unlik
fragment
found
patient
also
present
healthi
peopl
inde
greater
abund
fragment
patient
may
simpli
reflect
gener
heighten
activ
tumor
cellsnot
opn
produc
also
quickli
becom
cleav
caspas
enzym
tissu
end
result
vast
amount
opn
fragment
gener
releas
circul
clear
howev
intact
opn
produc
noncancer
tissu
becom
fragment
patient
hand
numer
report
describ
potent
biolog
activ
opn
fragment
includ
opn
fragment
gener
bear
rgd
domain
fig
recent
shown
promot
tumor
growth
metastasi
anoth
opn
fragment
could
remot
fit
candid
antigen
patient
kda
ctermin
peptid
gener
see
fig
could
bigger
molecular
weight
becom
glycosyl
phosphoryl
tumorigen
potenti
fragment
known
recent
takafuji
et
al
found
small
opn
fragment
residu
gener
seem
abl
induc
tumor
cell
invas
via
receptor
hepatocellular
carcinoma
thu
opn
fragment
circul
cancer
patient
bear
rgd
domain
intact
thrombinsensit
site
may
import
diagnost
prognost
biomarkerthey
could
well
determin
biolog
cancer
